ABSTRACT

Objective: To describe the prevalence and severity of sleep disorders and circadian alterations in COVID-19 patients four months after the acute phase of the disease.

Methods: This was a cross-sectional observational prospective study of patients with mild COVID-19, moderate COVID-19 (requiring hospitalization but no mechanical ventilation), or severe COVID-19 (with ARDS) four months after the acute phase of the disease. All patients underwent a home sleep apnea test and seven-day wrist actigraphy, as well as completing questionnaires to assess sleep quality and mental health.

Results: A total of 60 patients were included in the study. Of those, 17 were in the mild COVID-19 group, 18 were in the moderate COVID-19 group, and 25 were in the severe COVID-19 group. Sleep quality, as assessed by satisfaction, alertness, timing, efficiency, and duration scale scores, was found to be impaired in all three groups, which also had a high prevalence of unhealthy sleep, as assessed by the Pittsburgh Sleep Quality Index. The prevalence of insomnia was increased in all three groups, as assessed by the Insomnia Severity Index. The home sleep apnea test showed that the overall prevalence of obstructive sleep apnea was 60%, and seven-day wrist actigraphy showed that total sleep time was < 7 h in all three groups. Changes in quality of life and in the circadian rest-activity pattern were observed in all three groups. Conclusions: Sleep-related symptoms, changes in the circadian rest-activity pattern, and impaired mental health appear to be common in COVID-19 patients four months after the acute phase of the disease, severe COVID-19 being associated with a higher prevalence of obstructive sleep apnea.

Keywords: Sleep apnea, obstructive; Sleep disorders, circadian rhythm; COVID-19.
in accordance with current guidelines for reporting observational studies. The study protocol was approved by the institutional review boards of the Biobío Health Service and the Concepción Health Service (Code CEC-SSC: 07-20-26).

We included patients ≥ 18 years of age with an RT-PCR–confirmed diagnosis of SARS-CoV-2 infection between April and July of 2020. We included COVID-19 patients with varying degrees of disease severity, in accordance with the WHO definitions; severe COVID-19—severe hypoxemia and medical records of ARDS in accordance with the Berlin definition; moderate COVID-19—clinical or radiographic evidence of lower respiratory tract disease; and mild COVID-19—mild symptoms (e.g., fever, cough, and loss of taste or smell, without dyspnea). The patients with severe COVID-19 required ICU admission; those with moderate COVID-19 required hospitalization but no mechanical ventilation; and those with mild COVID-19 received clinical outpatient monitoring and supportive care. All of the patients included in the study were evaluated four months after the acute phase of COVID-19.

We excluded patients with previous respiratory comorbidities (asthma, COPD, and other respiratory diseases); patients receiving oxygen supplementation or noninvasive mechanical ventilation after hospitalization for COVID-19; and patients over 70 years of age. We also excluded patients who were lost to follow-up, those who were transferred to other hospitals or towns after discharge, and those with mental disability that might prevent them from completing the evaluations.

After giving written informed consent, all participants underwent physical examination and blood sample collection for further analysis. We collected data on demographics (age, sex, level of education, and place of residence), as well as on BMI (in kg/m²), waist circumference (in cm), neck circumference (in cm), hip circumference (in cm), and comorbidities at baseline.

**Sleep health**

At baseline, the study participants completed a self-report questionnaire including information on their sleep habits and sleep-related symptoms, similar to that employed by Mazzotti et al. Furthermore, the study participants completed the Spanish versions of the following questionnaires:

1. The satisfaction, alertness, timing, efficiency, and duration (SATED) scale. A SATED scale score of 10 indicates good sleep health.
2. The Pittsburgh Sleep Quality Index (PSQI). The PSQI ranges from 0 to 21. A score of 0 indicates no sleep difficulties, and a score of 21 indicates severe sleep difficulties. Participants with PSQI scores = 5 were classified as healthy in terms of sleep quality, whereas those with PSQI scores > 5 were classified as unhealthy.
3. The Epworth Sleepiness Scale (ESS). An ESS score > 10 was considered indicative of daytime sleepiness, and an ESS score of ≤ 10 was considered indicative of no daytime sleepiness.
4. The Insomnia Severity Index (ISI). The ISI evaluates the presence and severity of insomnia. An ISI score > 7 was used in order to indicate insomnia.
5. The STOP-Bang questionnaire. The STOP-Bang questionnaire was used in order to assess the risk of OSA. Scores of 0-2 were considered indicative of a low risk of OSA; scores of 3 and 4 were considered indicative of an intermediate risk of OSA; and scores of 5-8 were considered indicative of a high risk of OSA.
6. The Morningness-Eveningness Questionnaire (MEQ). The MEQ was used in order to assess chronotypes. MEQ scores of 16-30 were considered indicative of an extreme evening chronotype; MEQ scores of 31-41 were considered indicative of a moderate evening chronotype; MEQ scores of 42-58 were considered indicative of an intermediate chronotype; MEQ scores of 59-69 were considered indicative of a moderate morning chronotype; and MEQ scores of 70-86 were considered indicative of an extreme morning chronotype.

**Evaluation of OSA and the circadian rest-activity pattern**

OSA was evaluated by means of a home sleep apnea test (HSAT). The HSAT was performed in accordance with the American Academy of Sleep Medicine recommendations. The HSAT was manually scored by one researcher, who was blinded to the clinical and questionnaire data. The HSAT was performed with an ApneaLink Air™ home sleep testing device (ResMed, San Diego, CA, USA) between August and November of 2020. We collected data on the following variables: respiratory disturbance index (RDI—anapneas or hypopneas associated with 3% oxygen desaturation per hour), mean \( \text{SpO}_2 \), nadir \( \text{SpO}_2 \), total time with \( \text{SaO}_2 \) below 90%, and oxygen desaturation index ≥ 3%. OSA was defined as an RDI ≥ 5 events/h, and non-OSA was defined as an RDI of ≤ 4 events/h.

Seven-day wrist actigraphy was performed with an ActTrust 2 actigraph (Condor Instruments, São Paulo, Brazil) between August and November of 2020. The data collected by the actigraph were extracted with the use of ActStudio software (Condor Instruments). We examined the following parameters: time in bed (in min); total sleep time (TST, in min), defined as the number of minutes spent asleep during the time spent in bed; sleep onset latency (in min), defined as the number of minutes between bedtime and the first minute scored as sleep; sleep efficiency (in %), defined as the ratio between TST and time spent in bed; wake after sleep onset (in min), defined as the number of minutes awake after sleep onset; and arousals (in n).

To describe the shape and consistency of the 24-h rest-activity pattern, activity counts of 30-s epochs were obtained, and nonparametric circadian rhythm analysis was performed. We extracted the following data: interdaily stability (IS), which ranges from 0 to 1, representing the synchronization between
the internal rest-activity rhythm and the different zeitgebers; intraday variability (IV), which ranges from 0 to 2, representing the fragmentation of the rest-activity rhythm within each 24-h period; the most active 10-h period (M10); the least active 5-h period (L5); relative amplitude, which ranges from 0 to 1, representing the difference in magnitude of activity between active and rest phases (M10 − L5/M10 + L5); and the circadian function index, which ranges from 0 to 1 and is calculated as the average between IS, IV, and relative amplitude (IV values were inverted and normalized between 0 and 1). Additionally, we extracted the following variables through cosinor analysis: mesor, which represents the mean activity; amplitude, which represents the difference in magnitude of activity between the highest value of activity and the mean activity; and acrophase, which represents the time of peak activity.\(^{(24,29)}\)

**Evaluation of mental health**

HRQoL was assessed by the 12-Item Short-Form Health Survey (SF-12), and the results were presented in the domains of physical health and mental health.\(^{(30)}\) Quality of life was measured by the Hospital Anxiety and Depression Scale (HADS). Scores of 0-7 indicated normal quality of life, scores of 8-10 indicated borderline abnormal quality of life, and scores of 11-21 indicated abnormal quality of life.\(^{(31)}\) Depression was measured by the Beck Depression Inventory. Scores of 0-13 indicated minimal depression, scores of 14-19 indicated mild depression, scores of 20-28 indicated moderate depression, and scores of 29-62 indicated severe depression.\(^{(32)}\) Finally, fatigue was assessed by the Chalder Fatigue Scale.\(^{(33,34)}\)

**Statistical analysis**

In this study, we hypothesized that the severity of COVID-19 was associated with a risk of OSA and unhealthy sleep. On the basis of a study by Perger et al.,\(^{(35)}\) who reported undiagnosed OSA in 75% of patients with severe COVID-19, a baseline OSA prevalence of 25% from Chile,\(^{(36)}\) a power of 90%, and a p value of 0.05 (type I error), the estimated sample size was 16 per group.

Quantitative variables with normal or non-normal distribution were expressed as means and standard deviations. Qualitative variables were expressed as absolute and relative frequencies. The normality of the data distribution was examined with the Shapiro-Wilk test. The between-group differences established by the clinical variables were evaluated by the chi-square test and one-way ANOVA (for parametric variables) or by the Kruskal-Wallis test or Fisher’s exact test (for nonparametric variables). ANCOVA was performed to analyze sleep questionnaire data and HSAT results. BMI and age were used as covariates. Factors associated with a higher probability of OSA were identified by logistic regression analysis. The analysis was adjusted for sex, age (19-36, 37-46, 47-56, and 57-69 years), and nutritional status. The results of the analysis were presented as ORs and their respective 95% CIs. An OR > 1 indicated a higher probability of having OSA, and an OR of < 1 indicated a lower probability of having OSA. For all tests, a p value < 0.05 was considered statistically significant. All statistical analyses were performed with the IBM SPSS Statistics software package, version 25 (IBM Corporation, Armonk, NY, USA).

**RESULTS**

**Sociodemographic data and comorbidities**

A total of 60 COVID-19 patients were included in the study. Of those, 17 had mild COVID-19, 18 had moderate COVID-19, and 25 had severe COVID-19. Table 1 presents sociodemographic, anthropometric, and comorbidity data, by COVID-19 severity. The patients with severe COVID-19 were older than those with mild or moderate COVID-19. The prevalence of obesity was 64.7% in the moderate COVID-19 group and 64% in the severe COVID-19 group. Additionally, the prevalence of central obesity was high in the mild, moderate, and severe COVID-19 groups (66.7%, 82.4%, and 76.0%, respectively). The prevalences of diabetes mellitus, insulin resistance, and hypertension were highest in the moderate COVID-19 group (35.2%, 29.4%, and 47.0%, respectively).

**Sleep health and the circadian rest-activity pattern in COVID-19 patients during the recovery phase**

Table 2 shows the self-report data on sleep-related symptoms. Excessive daytime sleepiness and daytime tiredness were more prevalent in the mild COVID-19 group than in the moderate and severe COVID-19 groups, although the difference was not significant. In the moderate COVID-19 group, there was a high prevalence of difficulty falling asleep, difficulty maintaining sleep, and waking up too early. In the severe COVID-19 group, there was a high prevalence of difficulty maintaining sleep and waking up too early. The mean number of hours of sleep as reported by patients ranged from 6.4 h to 6.9 h.

The risk of OSA as assessed by the STOP-Bang questionnaire was higher in the severe and moderate COVID-19 groups (p = 0.038). The prevalence of OSA as assessed by the HSAT was 60% (27.8%, 64.7%, and 80.0% for the mild, moderate, and severe COVID-19 groups, respectively; Table 3). The logistic regression analysis showed that COVID-19 patients in the 57- to 69-year age bracket had a higher probability of having OSA than did those in the 19- to 36-year age bracket (OR = 22.709; p = 0.003). Neither nutritional status nor sex increased the probability of having OSA (Figure 1).

Sleep quality was found to be impaired in all three groups of COVID-19 patients. Mean SATED scale scores were 6.3 ± 3.0 in the mild COVID-19 group, 5.2 ± 2.3 in the moderate COVID-19 group, and 6.1 ± 2.2 in the severe COVID-19 group. Moreover, the PSQI showed that all three groups had a high prevalence of unhealthy sleep. An ESS score > 10 was found in...
Sleep health and the circadian rest-activity pattern four months after COVID-19

38.9% of the patients in the mild COVID-19 group, in 47.1% of those in the moderate COVID-19 group, and in 36.0% of those in the severe COVID-19 group.

The prevalence of insomnia as assessed by the ISI was increased in all three groups (50.0%, 82.4%, and 56.0% in the mild, moderate, and severe COVID-19 groups, respectively).

Actigraphy revealed a TST of < 7 h in all three groups (5 h 47 min and 54 s in the mild COVID-19 group, 6 h 04 min and 06 s in the moderate COVID-19 group, and 6 h 25 min and 30 s in the severe COVID-19 group). Sleep efficiency ranged from 86.3% to 87.4%. Circadian function was found to be impaired in all three groups. We found significant differences among the three groups regarding IV, which was higher in the moderate COVID-19 group than in the mild and severe COVID-19 groups (0.72 ± 0.11, 0.62 ± 0.09, and 0.64 ± 0.11, respectively). However, there were no significant differences among the three groups regarding the remaining variables. The acrophase was 15:33:05 (time) in the mild COVID-19 group, 15:44:00 (time) in the moderate COVID-19 group, and 15:17:33 (time) in the severe COVID-19 group.

### Clinical and mental health

Table 4 shows the results related to fatigue, HRQoL, mood, and depression, by COVID-19 severity. We found significant differences between the moderate COVID-19 group and the other groups regarding HADS anxiety domain scores. The mean HADS anxiety domain score in the moderate COVID-19 group was 8.6 ± 3.8, and 47% of the patients in that group reported abnormal values, in comparison with 16.7% and 12% of those in the mild and severe COVID-19 groups, respectively.

With regard to HRQoL, we found significant differences among the groups; mental health was found to be better in the mild COVID-19 group than in the moderate and severe COVID-19 groups. Furthermore, severe fatigue was found in all three groups (in 61.1% of the patients in the mild COVID-19 group, in 88.2% of those in the moderate COVID-19 group, and in 72.0% of those in the severe COVID-19 group).

### DISCUSSION

The main findings of the present study are as follows: 1) Sleep health is severely impaired four
months after the acute phase of COVID-19. 2) The overall prevalence of OSA was 60%, being as high as 80% in the severe COVID-19 group. 3) With regard to the circadian rest-activity pattern, the moderate COVID-19 group had higher IV and lower circadian function index, M10, L5, IS, mesor, and amplitude, as well as worse sleep quality as assessed by the PSQI. Moreover, the moderate COVID-19 group had a higher prevalence of insomnia, an intermediate chronotype (as determined by the MEQ), and higher anxiety (as assessed by the HADS).

After the acute phase of COVID-19, all three groups had poor sleep quality, low TST values, and prevalent insomnia. With regard to SF-12 scores, the moderate and severe COVID-19 groups had lower quality of physical and mental health than did the mild COVID-19 group. Recent evidence has shown that patients with severe COVID-19 have similar risk factors for OSA. We have previously shown that undiagnosed sleep-disordered breathing is associated with severe COVID-19 during the acute phase. Current evidence suggests that OSA is an independent risk factor for severe COVID-19 presentations and an increased risk of hospitalization.

The present study confirmed the physical and psychological consequences of COVID-19. The symptoms of the acute phase, four months after medical discharge, may be more significant than those thought to be essentially disorders associated with sleep. We investigated respiratory sleep disturbances, sleep quality disturbances, and sleep patterns in COVID-19 patients four months after discharge, providing prospective evidence of the relationship between sleep-disordered breathing and the severity of COVID-19. In addition, we found that all of the patients with COVID-19 in the present study had sleep disturbances, regardless of the severity of the disease. This evidence can contribute to a more precise profile of the sequelae of COVID-19 and to the development of comprehensive, long-term intervention programs covering these health problems.

In our study, we explored different parameters of circadian rest-activity rhythms. In the group of patients with moderate COVID-19, we found significant fragmentation of the rest-activity rhythm, as assessed by IV. This finding can be explained by the high prevalence of insomnia, an intermediate chronotype (as determined by the MEQ), and higher anxiety (as assessed by the HADS).

After the acute phase of COVID-19, all three groups had poor sleep quality, low TST values, and prevalent insomnia. With regard to SF-12 scores, the moderate and severe COVID-19 groups had lower quality of physical and mental health than did the mild COVID-19 group. Recent evidence has shown that patients with severe COVID-19 have similar risk factors for OSA. We have previously shown that undiagnosed sleep-disordered breathing is associated with severe COVID-19 during the acute phase. Current evidence suggests that OSA is an independent risk factor for severe COVID-19 presentations and an increased risk of hospitalization.

The present study confirmed the physical and psychological consequences of COVID-19. The symptoms of the acute phase, four months after medical discharge, may be more significant than those thought to be essentially disorders associated with sleep. We investigated respiratory sleep disturbances, sleep quality disturbances, and sleep patterns in COVID-19 patients four months after discharge, providing prospective evidence of the relationship between sleep-disordered breathing and the severity of COVID-19. In addition, we found that all of the patients with COVID-19 in the present study had sleep disturbances, regardless of the severity of the disease. This evidence can contribute to a more precise profile of the sequelae of COVID-19 and to the development of comprehensive, long-term intervention programs covering these health problems.

In our study, we explored different parameters of circadian rest-activity rhythms. In the group of patients with moderate COVID-19, we found significant fragmentation of the rest-activity rhythm, as assessed by IV. This finding can be explained by the high prevalence of comorbidities in the moderate COVID-19 group. Circadian and sleep disorders have been associated with harmful health outcomes in non-COVID-19 patients, including cardiometabolic and cognitive disorders. Interruptions in the sleep-wake cycle can influence circadian rhythms and homeostasis.

Recent evidence indicates that people who recover from COVID-19 continue to experience symptoms for months (long COVID-19 syndrome). In the present study, the prevalence of sleep disorders was found to be high. To our knowledge, this is the first study to describe sleep health after acute COVID-19. Moreover, we found symptoms associated with mental health (depression and anxiety), fatigue, and impaired HRQoL.

Our study showed a high prevalence of poor sleep quality and insomnia in all three groups of patients with COVID-19, as well as a decrease in the number of hours of sleep (which were below the recommended for optimal health). In addition, our study showed a low quality of life in the physical and mental health.

Table 2. Self-report data on sleep-related symptoms in the study population (N = 60).*  

| Variable                                      | Mild (n = 18) | COVID-19 Moderate (n = 17) | Severe (n = 25) | p*  |
|-----------------------------------------------|--------------|---------------------------|----------------|-----|
| Excessive daytime sleepiness                  | 52.9%        | 23.5%                     | 24.0%          | 0.15|
| Falling asleep involuntarily during the day   | 52.9%        | 35.3%                     | 28.0%          | 0.25|
| Dozing off while driving                      | 5.9%         | 5.9%                      | 8.00%          | 0.95|
| Difficulty falling asleep                     | 41.2%        | 70.6%                     | 36.0%          | 0.07|
| Difficulty maintaining sleep                  | 47.1%        | 64.7%                     | 56.0%          | 0.58|
| Waking up too early                           | 35.3%        | 58.8%                     | 52.0%          | 0.36|
| Taking a nap                                  | 17.6%        | 5.9%                      | 24.0%          | 0.30|
| Daytime tiredness                             | 58.8%        | 64.7%                     | 48.0%          | 0.54|
| Heavy nocturnal sweating                      | 47.1%        | 47.1%                     | 52.0%          | 0.93|
| Observed apneas                               | 11.8%        | 17.6%                     | 20.0%          | 0.78|
| Morning headaches                             | 47.1%        | 52.9%                     | 36.0%          | 0.53|
| Number of hours of sleep (on weekdays)       | 6.9 ± 0.9    | 6.4 ± 1.4                 | 6.7 ± 1.9      | 0.58|
| Number of hours of sleep (on weekends)       | 8.2 ± 1.5    | 7.7 ± 1.5                 | 7.6 ± 2.4      | 0.09|
| Nocturia                                      | 41.2%        | 70.6%                     | 64.0%          | 0.17|
| Apnea during the night                        | 23.5%        | 35.3%                     | 36.0%          | 0.66|
| Restless legs syndrome                        | 47.1%        | 47.1%                     | 52.0%          | 0.93|
| Severe snoring                                | 23.5%        | 23.5%                     | 28.0%          | 0.92|
| Taking sleeping pills                         | 17.6%        | 35.3%                     | 24.0%          | 0.48|

*Data expressed as % or mean ± SD. *One-way ANOVA and the chi-square test. A value of p < 0.05 was considered significant for all analyses.
## Table 3. Sleep questionnaire data and home sleep apnea test results in the study population (N = 60).^a

| Variable                                      | Mild (n = 18) | Moderate (n = 17) | Severe (n = 25) | p*   |
|-----------------------------------------------|--------------|------------------|----------------|------|
| **Sleep questionnaires**                      |              |                  |                |      |
| SATED scale score                            | 6.3 ± 3.0    | 5.2 ± 2.3        | 6.1 ± 2.2      | 0.470|
| PSQI score                                    | 8.5 ± 4.2^a  | 12.3 ± 4.4^a     | 9.3 ± 4.5^a    | 0.049|
| Healthy sleep (≤ 5)                           | 16.7%        | 11.8%            | 12.0%          | 0.883|
| Unhealthy sleep (> 5)                         | 83.3%        | 88.2%            | 88.0%          |      |
| ESS score                                     | 7.5 ± 5.5    | 9.2 ± 5.2        | 8.2 ± 5.1      | 0.511|
| Nonsleepy (≤ 10)                              | 61.1%        | 52.9%            | 64.0%          | 0.768|
| Sleepy (> 10)                                 | 38.9%        | 47.1%            | 36%            |      |
| ISI                                           | 8.2 ± 6.9    | 12.9 ± 6.2       | 9.4 ± 6.1      | 0.082|
| Without insomnia                              | 50%          | 17.6%            | 44.0%          | 0.108|
| With insomnia                                 | 50%          | 82.4%            | 56%            |      |
| STOP-Bang questionnaire score                 | 2.2 ± 1.7^a  | 3.5 ± 2.2^a      | 3.6 ± 1.6^a    | 0.047|
| No risk of OSA                                 | 27.8%        | 0%               | 4.0%           | 0.038|
| Low risk of OSA                               | 27.8%        | 41.2%            | 16.0%          |      |
| Intermediate risk of OSA                      | 33.3%        | 35.3%            | 48.0%          |      |
| High risk of OSA                              | 11.1%        | 23.5%            | 32.0%          |      |
| MEQ score                                     | 54.1 ± 8.7   | 55.2 ± 7.9       | 59.5 ± 7.4     | 0.208|
| **Home sleep apnea test**                     |              |                  |                |      |
| RDI                                           | 7.3 ± 10.2   | 12.2 ± 10.5      | 12.6 ± 9.5     | 0.779|
| 0-4 events/h (non-OSA)                        | 72.2%        | 35.3%            | 20.0%          | 0.002|
| ≥ 5 events/h (OSA)                            | 27.8%        | 64.7%            | 80.0%          |      |
| Obstructive apneas, events/h                  | 1.79 ± 2.87  | 1.41 ± 2.70      | 2.89 ± 5.53    | 0.686|
| Central apneas, events/h                      | 2.3 ± 4.5    | 3.8 ± 7.8        | 2.1 ± 3.5      | 0.595|
| Hypopnea index, events/h                      | 4.92 ± 7.16  | 6.91 ± 8.59      | 7.12 ± 5.18    | 0.747|
| ODI ≥ 3%                                      | 7.2 ± 11.7   | 11.2 ± 11.9      | 11.6 ± 9.7     | 0.489|
| Snoring events                                | 608.6 ± 950.8| 966.8 ± 1,591.9  | 958.7 ± 1,207.2| 0.499|
| T90%                                          | 2.4 ± 5.6    | 7.5 ± 14.6       | 12.1 ± 22.0    | 0.352|
| Mean SpO2                                     | 95.2 ± 1.2^a | 93.9 ± 1.5^b     | 93.6 ± 1.8^b   | 0.041|
| Nadir SpO2                                    | 85.8 ± 7.6   | 83.9 ± 5.6       | 82.4 ± 5.6     | 0.475|
| **Actigraphy**                                |              |                  |                |      |
| Time in bed, min                              | 400.9 ± 101.0| 410.1 ± 96.2     | 434.5 ± 99.4   | 0.445|
| Total sleep time, min                         | 347.9 ± 105.3| 364.1 ± 96.3     | 385.5 ± 90.6   | 0.399|
| Sleep onset latency, min                      | 2.0 ± 1.5    | 2.1 ± 1.7        | 2.2 ± 2.3      | 0.965|
| Sleep efficiency, %                           | 87.4 ± 5.7   | 86.3 ± 8.4       | 86.9 ± 6.2     | 0.912|
| WASO, min                                     | 42.2 ± 20.0  | 42.9 ± 19.2      | 47.2 ± 26.0    | 0.759|
| Arousals                                      | 7.7 ± 3.9    | 7.1 ± 3.6        | 7.3 ± 4.3      | 0.948|
| **Circadian rhythm**                          |              |                  |                |      |
| CFI                                           | 0.73 ± 0.06  | 0.71 ± 0.05      | 0.73 ± 0.06    | 0.520|
| M10                                           | 6,371.0 ± 1,170.3| 6,024.0 ± 1,237.6| 6,227.1 ± 1,629.6| 0.794|
| LS                                            | 79.9 ± 48.5 | 62.0 ± 27.3      | 69.6 ± 36.7    | 0.435|
| RA                                            | 0.98 ± 0.01  | 0.98 ± 0.01      | 0.97 ± 0.02    | 0.959|
| IS                                            | 0.5 ± 0.1    | 0.4 ± 0.1        | 0.5 ± 0.1      | 0.428|
| IV                                            | 0.62 ± 0.09^a| 0.72 ± 0.11^b    | 0.64 ± 0.11^a  | 0.030|
| Mesor                                         | 3,012.5 ± 635.3| 2,777.8 ± 785.4  | 2,789.8 ± 701.7| 0.593|
| Amplitude                                     | 2,417.7 ± 682.5| 2,162.7 ± 585.2  | 2,416.0 ± 688.8| 0.441|
| Acrophase                                     | 15:33:05     | 15:44:00         | 15:17:33       |      |

*SATED: satisfaction, alertness, timing, efficiency, and duration; PSQI: Pittsburgh Sleep Quality Index; ESS: Epworth Sleepiness Scale; ISI: Insomnia Severity Index; OSA: obstructive sleep apnea; MEQ: Morningness-Eveningness Questionnaire; RDI: respiratory disturbance index; ODI: oxygen desaturation index; T90%: total time with SaO2 below 90%; WASO: wake after sleep onset; CFI: circadian function index; M10: the most active 10-h period; LS: the least active 5-h period; RA: relative amplitude; IS: interdaily stability; and IV: intraday variability. *Data expressed as mean ± SD or %. *One-way ANOVA and the chi-square test. Different letters in the same row indicate significant differences between groups (one-way ANOVA and post hoc analysis with the Bonferroni test). ANCOVA was performed to analyze sleep questionnaire data and home sleep apnea test results. BMI and age were used as covariates. A value of p < 0.05 was considered significant for all analyses.

---

J Bras Pneumol. 2022;48(3):e20210398
domains of the SF-12, as well as a high prevalence of severe fatigue.

Previous studies have evaluated the risk of sequelae after COVID-19, focusing on clinical parameters, pulmonary function tests, and quality of life parameters. Our study opens up another dimension to explore during the recovery phase of COVID-19 infection (i.e., sleep health), and our results are relevant to current clinical practice.

One of the limitations of the present study is that the sample size was small (60 patients). Future studies exploring COVID-19 symptoms in larger cohorts should include sleep health in their evaluations. Another limitation is the lack of a control group, meaning that we were unable to compare the effects of COVID-19 severity on the study variables.

We found a high prevalence of sleep-related symptoms in the group of patients with moderate COVID-19. Future studies investigating such patients should examine the psychological and sleep sequelae of COVID-19. The patients with moderate COVID-19 in the present study had worse sleep quality and higher anxiety than did those with mild or severe COVID-19. This might be due to the high prevalence of insulin resistance, diabetes mellitus, and hypertension in the moderate COVID-19 group. It has recently been shown that a high burden of comorbidities is associated with low sleep quality and high anxiety.

Yet another limitation is that we used subjective measures of different sleep parameters. However, the prevalence of sleep disorders in the present study was high in all three groups of patients.

In conclusion, our findings show several sleep-related symptoms, as well as changes in the circadian rest-activity pattern, together with impaired mental health, in COVID-19 patients four months after the acute phase of the disease. Further studies are needed to confirm these findings and understand the underlying mechanisms.

ACKNOWLEDGMENTS

We would like to thank Condor Instruments (São Paulo, Brazil) for their collaboration. We would also like to express our gratitude to Luis Filipe Rossi, Rodrigo T. Okamoto, and Jhony Collis for their technical support.

AUTHOR CONTRIBUTIONS

GL: study design and guarantor of the article; MH-B, JL, DE, IC, and EN-L: data extraction and analysis; GL, IC, and MH-B: statistical analysis; MH-B, IC, EN-L, GL, AT, and FB: drafting of the manuscript; GL, EN-L, AT,
Table 4. Health-related quality of life, mood, depression, and fatigue in the study population (N = 60).*

| Variable                                    | Mild (n = 18) | COVID-19 Moderate (n = 17) | Severe (n = 25) | p*     |
|---------------------------------------------|---------------|----------------------------|-----------------|-------|
| **Mental health**                           |               |                            |                 |       |
| HADS-A score                                | 5.6 ± 4.6a    | 8.6 ± 3.8b                 | 5.6 ± 3.7b      | 0.042 |
| Normal                                      | 77.8%         | 47.1%                      | 72.0%           | 0.067 |
| Borderline abnormal                         | 5.6%          | 5.9%                       | 16.0%           |       |
| Abnormal                                    | 16.7%         | 47.1%                      | 12.0%           |       |
| HADS-D score                                | 5.0 ± 4.6     | 5.9 ± 3.6                  | 3.4 ± 2.9       | 0.096 |
| Normal                                      | 72.2%         | 70.6%                      | 84.0%           | 0.305 |
| Borderline abnormal                         | 11.1%         | 11.8%                      | 16.0%           |       |
| Abnormal                                    | 16.7%         | 17.6%                      | 0%              |       |
| BDI score                                   | 8.2 ± 9.4     | 12.1 ± 8.1                 | 8.9 ± 6.8       | 0.308 |
| No depression                               | 77.8%         | 76.5%                      | 72.0%           | 0.744 |
| Mild depression                             | 11.1%         | 5.9%                       | 20.0%           |       |
| Moderate depression                         | 5.6%          | 11.8%                      | 8.0%            |       |
| Severe depression                           | 5.6%          | 5.9%                       | 0%              |       |
| **Health-related quality of life**          |               |                            |                 |       |
| SF-12, mental health score                  | 50.26 ± 7.77a | 40.37 ± 11.44a             | 41.21 ± 10.09a  | 0.005 |
| SF-12, physical health score                | 45.0 ± 11.06  | 43.33 ± 12.44              | 49.86 ± 8.93    | 0.123 |
| **Fatigue**                                 |               |                            |                 |       |
| Chalder Fatigue Scale score                 | 4.4 ± 3.4     | 6.6 ± 2.3                  | 5.1 ± 2.7       | 0.079 |
| Total score                                 | 13.3 ± 10.2   | 19.8 ± 6.9                 | 15.4 ± 8.0      | 0.079 |
| Severe fatigue                              | 61.1%         | 88.2%                      | 72.0%           | 0.189 |

HADS-A: Hospital Anxiety and Depression Scale, anxiety domain; HADS-D: Hospital Anxiety and Depression Scale, depression domain; BDI: Beck Depression Inventory; and SF-12: 12-Item Short-Form Health Survey. *Data expressed as mean ± SD or %. p*One-way ANOVA and the chi-square test. Different letters in the same row indicate significant differences between groups (one-way ANOVA and post hoc analysis with the Bonferroni test). A value of p < 0.05 was considered significant for all analyses.

and FB: critical revision of the manuscript for important intellectual content; MH-B, GL, IC, DE, JL, EN-L, AT, and FB: approval of the final version.

CONFLICTS OF INTEREST

None declared.

REFERENCES

1. Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):640. https://doi.org/10.1186/s12879-020-05371-2
2. Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. 2020;215:108427. https://doi.org/10.1016/j.clim.2020.108427
3. Worldometer [homepage on the Internet]. Dover (DE): Worldometers.info [cited 2021 Feb 23]. COVID-19 Coronavirus Pandemic. Available from: https://www.worldometers.info/coronavirus/
4. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220-232. https://doi.org/10.1016/S0140-6736(20)32656-8
5. González J, Benítez ID, Carmona P, Santisteve S, Monge A, Moncusí-Moix A, et al. Pulmonary Function and Radiologic Features in Survivors of Critical COVID-19: A 3-Month Prospective Cohort. Chest. 2021;160(1):187-198. https://doi.org/10.1016/j.chest.2021.02.062
6. Writing Committee for the COMEBAC Study Group, Morin L, Savale L, Pharm T, Colle R, Figueiredo S, et al. Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19 [published correction appears in JAMA. 2021 Nov 9;326(18):1874]. JAMA. 2021;325(15):1525-1534. https://doi.org/10.1001/jama.2021.3331
7. Nalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615. https://doi.org/10.1038/s41591-021-01283-z
8. Mello MT, Silva A, Guerreiro RC, da-Silva FR, Esteves AM, Poyares D, et al. Sleep and COVID-19: considerations about immunity, pathophysiology, and treatment. Sleep Sci. 2020;13(3):199-209.
9. Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19: it’s not over until?. Clin Microbiol Infect. 2021;27(4):506-508. https://doi.org/10.1016/j.cmi.2020.12.001
10. Andreani TS, Itoh TQ, Yildirim E, Hwangbo DS, Allada R. Genetics of Circadian Rhythms. Sleep Med Clin. 2015;10(4):413-421. https://doi.org/10.1016/j.jsmc.2015.08.007
11. Truong KK, Lam MT, Grandner MA, Sassoon CS, Malhotra A. Timing Matters: Circadian Rhythm in Sepsis, Obstructive Lung Disease, Obstructive Sleep Apnea, and Cancer. Ann Am Thorac Soc. 2016;13(7):1144-1154. https://doi.org/10.1513/AnnalsATS.201602-125FR
12. Labarca G, Henriquez-Beltran M, Llerena F, Erices G, Lastra J, Enos D, et al. Undiagnosed sleep disorder breathing as a risk factor for critical COVID-19 and pulmonary consequences at the midterm follow-up [published online ahead of print, 2021 Feb 19]. Sleep Med. 2021;S1389-9457(21)00128-3. https://doi.org/10.1016/j.sleep.2021.02.029
13. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. https://doi.org/10.1371/journal.pmed.0040296
14. Ferguson ND, Fan E, Camporota L, Anzueto A, Beale R, et al. The Berlin definition of ARDS: an expanded rationale,
justification, and supplementary material [published correction appears in Intensive Care Med. 2012 Oct;38(10):1735-2. Intensive Care Med. 2012;38(10):1735-1738. https://doi.org/10.1007/s00134-012-2682-1]

15. Mazzotti DR, Keenan BT, Lim DC, Gottlieb DJ, Kim J, Pack AI. Symptom Subtypes of Obstructive Sleep Apnea Predict Incidence of Cardiovascular Outcomes. Am J Respir Crit Care Med. 2019;200(4):493-506. https://doi.org/10.1164/rccm.201808-1509OC

16. Buysse DJ. Sleep health: can we define it? Does it matter?. Sleep. 2014;37(1):9-17. https://doi.org/10.5665/sleep.3298

17. Mollayeva T, Thuraiarajh P, Burton K, Mollayeva S, Shapiro CM, Colantonio A. The Pittsburgh sleep quality index as a screening tool for sleep dysfunction in clinical and non-clinical samples: A systematic review and meta-analysis. Sleep Med Rev. 2016;25:52-73. https://doi.org/10.1016/j.smrv.2015.01.009

18. Morin CM, Belleville G, Belanger L, Ivers H. The Insomnia Severity Index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-608. https://doi.org/10.1093/sleep/34.5.601

19. Chung F, Liao P, Farney R. Correlation between the STOP-Bang Score and the Severity of Obstructive Sleep Apnea. Anesthesiology. 2015;122(6):1436-1437. https://doi.org/10.1097/ALN.0000000000000866

20. Chung F, Yang Y, Brown R, Liao P. Alternative scoring models of STOP-bang questionaire improve specificity to detect undiagnosed obstructive sleep apnea. J Clin Sleep Med. 2014;10(9):951-958. https://doi.org/10.5664/jcsm.4022

21. Perez Valdivieso JR, Bes-Rastrollo M. Concerns about the validation of the Berlin Questionnaire and American Society of Anesthesiologist checklist as screening tools for obstructive sleep apnea in surgical patients. Anesthesiology. 2005;110(1):194-195. https://doi.org/10.1097/00134554-200501000-00014

22. Home JA, Ostberg D. A self-assessment questionnaire to determine morningness-eveningness in human circadian rhythms. Int J Chronobiol. 1976;4(2):97-110. https://doi.org/10.1037/t02254-000

23. Kapur V, Auckley DH, Chowdhuri S, Kuhlmann DC, Mehra R, Ramar K, et al. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017;13(3):479-504. https://doi.org/10.5664/jcsm.6506

24. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollock CP. The role of actigraphy in the study of sleep and circadian rhythms. Sleep. 2005;28(3):342-392. https://doi.org/10.1093/sleep/28.3.342

25. Panuthi S, Brooks LJ, D’Ambrosio C, Hall WA, Kotagal S, Lloyd RM, et al. Consensus Statement of the American Academy of Sleep Medicine on the Recommended Amount of Sleep for Healthy Children: Methodology and Discussion. J Clin Sleep Med. 2018;14(11):1549-1561. https://doi.org/10.5664/jcsm.8288

26. Renssen N, Steur LHM, Wijnen N, van Someren EJV, Kaspers GJL, van Litsenburg RRL. Actigraphic estimates of sleep and the sleep-wake rhythm, and 6-sulfatoxymelatonin levels in healthy Dutch children. Chronobiol Int. 2020;37(5):660-672. https://doi.org/10.1080/07420528.2020.1756841

27. Cole RJ, Kripke DF, Gruen W, Mullaney DJ, Gillin JC. Automatic sleep/wake identification from wrist activity. Sleep. 1992;15(6):461-469. https://doi.org/10.1093/sleep/15.5.461

28. Thomas KA, Burt RL. Circadian research in mothers and infants: how many days of actigraphy data are needed to fit cosinor parameters?. J Nurs Meas. 2008;16(1):201-206. https://doi.org/10.1891/1061-3749.16.3.201

29. Gonçalves BS, Adamowicz T, Louzada FM, Moreno CR, Araújo JF. A fresh look at the use of non-parametric analysis in actimetry. Sleep Rev. 2015;20:84-91. https://doi.org/10.1016/j.srev.2014.06.002

30. Vera-Villarreal P, Silva J, Celia-Ateñas K, Pavez F. Evaluation of the SF-12: usefulness of the mental health scale [Article in Spanish]. Rev Med Chil. 2014;142(10):1275-1283. https://doi.org/10.4067/S0034-98872014001000007

31. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002;52(2):69-77. https://doi.org/10.1016/S0022-3999(01)00296-3

32. Jackson-Koku G. Beck Depression Inventory, Occup Med (Lond). 2016;66(2):174-175. https://doi.org/10.1093/occmed/kqv087

33. Hewlett S, Dures E, Almeida C. Measures of fatigue: Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional Questionnaire (BRAF MDoC), Bristol Rheumatoid Arthritis Fatigue Numerical Rating Scales (BRAF NRS) for severity, effect, and coping, Chalder Fatigue Questionnaire (CFQ), Checklist Individual Strength (CIS20R and CIS8R), Fatigue Severity Scale (FSS), Functional Assessment Chronic Illness Therapy (Fatigue) (FACT-F), Multi-Dimensional Fatigue Inventory (MDFI), Pediatric Quality Of Life (PedsQL) Multi-Dimensional Fatigue Scale, Profile of Fatigue (ProFi), Short Form 36 Vitality Subscale (SF-36 VT), and Visual Analog Scales (VAS). Arthritis Care Res (Hoboken). 2011;63 Suppl 11:S263-S286. https://doi.org/10.1002acr.20579

34. Jackson C. The Chalder Fatigue Scale (CF1), Occup Med (Lond). 2015;65(11):86. https://doi.org/10.1093/occmed/kqo1168

35. Parger E, Saranna D, Pengo M, Meriggi P, Lombard C, Parati G. Sleep-disordered Breathing among Hospitalized Patients with COVID-19. Am J Respir Crit Care Med. 2021;202(2):239-241. https://doi.org/10.1164/rccm.202010-3886LE

36. Sadlás Perfiliel F, Brockmann Veloso P, Santín Martínez J, Fuentes-López E, Leiva Rodriguez I, Valdivia Cabrera G. Prevalence of obstructive sleep apnea syndrome in Chilean adults. A sub-study of the national health survey, 2016/17 [Article in Spanish]. Rev Med Chil. 2020;148(7):895-905. https://doi.org/10.4067/S0034-98872020000700099

37. Silva FRD, Queirós RC, Andrade HA, Staerel E, Silva A, de Mello MT. Does the compromised sleep and circadian disruption of night and shiftworkers make them highly vulnerable to 2019 coronavirus disease COVID-19?. Chronobiol Int. 2020;37(1):607-617. https://doi.org/10.1080/07420528.2020.1756841

38. Consensus Conference Panel, Watson NF, Badi MS, Belenyk G, Bilwase DL, Buxton OM, et al. Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society. J Clin Sleep Med. 2015;11(8):591-592. https://doi.org/10.5664/jcsm.4758

39. Zhu B, Vincent C, Kapella MC, Quinn L, Collins EG, Ruggiero L, et al. Sleep disturbance in people with diabetes: A concept analysis. J Clin Nurs. 2018;27(1-2):e50-e60. https://doi.org/10.1111/jocn.14010

40. Zampogna E, Ambrosino N, Saderi L, Sotgiu G, Bottini P, Pignatti P, et al. Time course of exercise capacity in patients recovering from COVID-19-associated pneumonia. J Bras Pneumol. 2021;47(4):e20210076. https://doi.org/10.13461/1806-3756/e20210076